Clinical Trial Detail

NCT ID NCT03425331
Title Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Dana-Farber Cancer Institute
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST